Teclistamab serves as a revolutionary novel anti-BCMA antibody drug construct, designated JNJ-64007957, demonstrating immense promise in the therapy of multiple myeloma. This innovative agent works by specifically binding BCMA, a marker highly expressed on the surface of myeloma cells. Through this targeted mechanism, teclistamab administers a pote